Galmed Pharma (GLMD) Reports In-Line Q1 EPS

Galmed Pharma (NASDAQ: GLMD) reported Q1 EPS of ($0.38), in-line with the analyst estimate of ($0.38).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Nike names former Pfizer CFO David Denton as new finance chief